Inmune Bio 8-K: General Corporate Info, NASDAQ Listing Confirmed
Ticker: INMB · Form: 8-K · Filed: Jan 30, 2024 · CIK: 1711754
| Field | Detail |
|---|---|
| Company | Inmune Bio, Inc. (INMB) |
| Form Type | 8-K |
| Filed Date | Jan 30, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: corporate-governance, administrative, regulatory-filing
TL;DR
**Inmune Bio filed a routine 8-K, no major news, just corporate info and NASDAQ listing confirmation.**
AI Summary
Inmune Bio, Inc. filed an 8-K on January 30, 2024, primarily to disclose general corporate information and confirm its registration on The NASDAQ Stock Market LLC under the trading symbol INMB. This filing is largely administrative, indicating no new material events beyond standard corporate updates. For investors, this filing simply reaffirms the company's current public listing status and provides updated contact information, offering no new insights into its financial performance or operational changes.
Why It Matters
This filing is largely administrative, confirming Inmune Bio's listing on NASDAQ and providing updated contact details, with no immediate impact on stock valuation or operational outlook.
Risk Assessment
Risk Level: low — This 8-K filing is purely administrative and does not contain any information that would introduce new risks or change the company's risk profile.
Analyst Insight
This filing is purely administrative and provides no new material information for investment decisions. Investors should continue to monitor future filings for operational or financial updates.
Key Numbers
- $0.001 — par value per share (This is the nominal par value of Inmune Bio's common stock.)
Key Players & Entities
- Inmune Bio, Inc. (company) — the registrant filing the 8-K
- The NASDAQ Stock Market LLC (company) — the exchange where Inmune Bio's common stock is registered
- INMB (company) — the trading symbol for Inmune Bio's common stock
- January 30, 2024 (date) — date of earliest event reported and filing date
- $0.001 (dollar_amount) — par value per share of common stock
FAQ
What is the primary purpose of Inmune Bio, Inc.'s 8-K filing dated January 30, 2024?
The primary purpose of Inmune Bio, Inc.'s 8-K filing dated January 30, 2024, is to provide general corporate information, including its registration on The NASDAQ Stock Market LLC and its trading symbol INMB, under Item 1.01 and Item 9.01, which covers Regulation FD Disclosure and Financial Statements and Exhibits, respectively.
On which stock exchange is Inmune Bio, Inc.'s common stock registered?
Inmune Bio, Inc.'s common stock, with a par value of $0.001 per share, is registered on The NASDAQ Stock Market LLC, as stated in the 'Securities registered pursuant to Section 12(b) of the Act' section of the filing.
What is the trading symbol for Inmune Bio, Inc. on its registered exchange?
The trading symbol for Inmune Bio, Inc. on The NASDAQ Stock Market LLC is INMB, as indicated in the 'Trading Symbol(s)' column of the filing.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported in this 8-K filing is January 30, 2024, as specified under 'Date of Report (Date of earliest event reported): January 30, 2024'.
What is Inmune Bio, Inc.'s state of incorporation and IRS Employer Identification Number?
Inmune Bio, Inc.'s state of incorporation is Nevada, and its IRS Employer Identification Number is 47-5205835, according to the company data section of the filing.
Filing Stats: 575 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-01-30 08:02:36
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per shares INMB The NASDAQ Stock Ma
Filing Documents
- ea192396-8k_inmune.htm (8-K) — 24KB
- ea192396ex99-1_inmune.htm (EX-99.1) — 10KB
- ex99-1_001.jpg (GRAPHIC) — 2KB
- 0001213900-24-007582.txt ( ) — 210KB
- inmb-20240130.xsd (EX-101.SCH) — 3KB
- inmb-20240130_lab.xml (EX-101.LAB) — 33KB
- inmb-20240130_pre.xml (EX-101.PRE) — 22KB
- ea192396-8k_inmune_htm.xml (XML) — 4KB
01 Regulation
Item 7.01 Regulation FD Disclosure. On January 30, 2024, INmune Bio Inc. (the "Company"), issued a press release announcing that the Company received FDA correspondence confirming that the full clinical hold on the Company's Alzheimer's disease clinical trial program has been lifted. Phase II trial patient enrollment is anticipated to be complete in mid-2024. Top line data is expected approximately six months after the last patient is enrolled. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item 7.01 and Item 9.01 (including Exhibit 99.1), is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities under that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, amended (the "Securities Act"). In addition, the information in this Item 7.01 disclosure, including Exhibit 99.1, shall not be incorporated by reference into the filings of the Company under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01 Financial statements and Exhibits
Item 9.01 Financial statements and Exhibits (d) Exhibits. 99.1 Press Release dated January 30, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INMUNE BIO INC. Date: January 30, 2024 By: /s/ David Moss David Moss Chief Financial Officer 2